阿司匹林预防心脑血管病的神话已破灭
▲每年一度的ESC是全球规模最大、最具影响力的国际心血管学术会议
▲ ESC 2018德国慕尼黑会场
▲两项研究成果已被各大国外媒体报道
对于预防心脑血管病
服用阿司匹林风险远大于收益
• 主要副作用1：增加人体出血风险
• 主要副作用2：破坏胃肠道内壁
柳叶刀都说了，你的阿司匹林得按胖瘦来吃。
如果世上只有一种神药，那么它的名字一定是——阿司匹林。
如果患者体重≤ 70 kg，那么其阿司匹林用药剂量和现有治疗并无不同，不需调整用药。 如果患者体重≥ 90 kg，那么现有阿司匹林治疗方案很可能是不足量的，可以在咨询专科医生后进行药物用量的调整。 如果患者体重大于70 kg，但小于90 kg，那就需要根据用药目的判定，咨询专科医生后进行决断。
参考文献：（上下滑动查看更多）
[1] Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial[J]. The Lancet, 2018:S014067361831924X.
[2] The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018; doi:10.1056/NEJMoa1804988.
[3] Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018; August 27, 2018.
[4] Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018 Aug 27.
[5] Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018 Sep 23.
[6] Clinical Benefit of Evolocumab by Severity and Extent of CoronaryArteryDisease:AnAnalysisfromFOURIER[J].Circulation,2018:CIRCULATIONAHA.118.034309.
[7] TWO YEAR ANALYSIS OF THE SAFETY AND TOLERABILITY OF EVOLOCUMAB: THE OSLER-1 STUDY[J]. Journal of the American College of Cardiology, 2015, 65(10):A1364.
[8] Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018;doi:10.1016/S0140-6736(18)31719-7.
[9] Online Angiography Image-Based FFR Assessment During Coronary Catheterization: A Single-Center Study.[J]. Journal of Invasive Cardiology, 2018.
[10] Kornowski R , Vakninassa H , Assali A , et al. Online Angiography Image-Based FFR Assessment During Coronary Catheterization: A Single-Center Study.[J]. Journal of Invasive Cardiology, 2018.
[11] Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J]. European Journal of Heart Failure, 2014, 16(7):817-825.
[12] Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2018; doi:10.1056/NEJMoa1812851.
